Karyopharm Therapeutics Inc.骨髓纤维化III期Sentry试验顶线数据预计2026年3月发布

美股速递2025-10-08

Karyopharm Therapeutics Inc.宣布，其针对骨髓纤维化适应症的III期Sentry临床试验进展顺利，顶线数据预计将于2026年3月按计划公布。

该项关键性试验旨在评估公司核心药物在治疗骨髓纤维化患者中的疗效和安全性。骨髓纤维化是一种罕见的血液肿瘤疾病，目前治疗选择有限，患者迫切需要新的治疗方案。

试验数据的如期发布将为公司后续的监管申请和商业化进程奠定重要基础。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1177101561?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-08 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177101561","market":"us","top_or_hot":-1,"title":"Karyopharm Therapeutics Inc.骨髓纤维化III期Sentry试验顶线数据预计2026年3月发布","media":"美股速递","content":"<p>Karyopharm Therapeutics Inc.宣布，其针对骨髓纤维化适应症的III期Sentry临床试验进展顺利，顶线数据预计将于2026年3月按计划公布。</p>\n<p>该项关键性试验旨在评估公司核心药物在治疗骨髓纤维化患者中的疗效和安全性。骨髓纤维化是一种罕见的血液肿瘤疾病，目前治疗选择有限，患者迫切需要新的治疗方案。</p>\n<p>试验数据的如期发布将为公司后续的监管申请和商业化进程奠定重要基础。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Karyopharm Therapeutics Inc.骨髓纤维化III期Sentry试验顶线数据预计2026年3月发布</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKaryopharm Therapeutics Inc.骨髓纤维化III期Sentry试验顶线数据预计2026年3月发布\n</h2>\n\n<h4 class=\"meta\">\n\n2025-10-08 19:03 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Karyopharm Therapeutics Inc.宣布，其针对骨髓纤维化适应症的III期Sentry临床试验进展顺利，顶线数据预计将于2026年3月按计划公布。\n该项关键性试验旨在评估公司核心药物在治疗骨髓纤维化患者中的疗效和安全性。骨髓纤维化是一种罕见的血液肿瘤疾病，目前治疗选择有限，患者迫切需要新的治疗方案。\n试验数据的如期发布将为公司后续的监管申请和商业化进程奠定重要基础。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1177101561","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177101561","pubTimestamp":1759921432,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Karyopharm Therapeutics Inc.宣布，其针对骨髓纤维化适应症的III期Sentry临床试验进展顺利，顶线数据预计将于2026年3月按计划公布。\n该项关键性试验旨在评估公司核心药物在治疗骨髓纤维化患者中的疗效和安全性。骨髓纤维化是一种罕见的血液肿瘤疾病，目前治疗选择有限，患者迫切需要新的治疗方案。\n试验数据的如期发布将为公司后续的监管申请和商业化进程奠定重要基础。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","KPTI":"Karyopharm Therapeutics Inc."},"translate_title":"Karyopharm Therapeutics Inc. Myelofibrosis Phase III Sentry Trial Top-Line Data Expected March 2026","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KPTI":1},"content_text":"Karyopharm Therapeutics Inc.宣布，其针对骨髓纤维化适应症的III期Sentry临床试验进展顺利，顶线数据预计将于2026年3月按计划公布。\n该项关键性试验旨在评估公司核心药物在治疗骨髓纤维化患者中的疗效和安全性。骨髓纤维化是一种罕见的血液肿瘤疾病，目前治疗选择有限，患者迫切需要新的治疗方案。\n试验数据的如期发布将为公司后续的监管申请和商业化进程奠定重要基础。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177101561","isCrawlerRequest":true}